Form D · Pharmaceuticals

Unity Biotechnology, Inc.

Brisbane, CA · CIK 0001463361

Offering snapshot reported Mar 27, 2018 · SEC filing

Reported sold
$55M
Offering amount: $60M
Investors reported
27
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 15, 2018
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 27, 2018Initial$55,049,948No comparison27SEC filing
Aug 21, 2017Amendment$151,230,099$42,909,982vs Dec 1, 201638SEC filing
Dec 1, 2016Initial$108,320,117No comparison26SEC filing
Jul 15, 2013Initial$2,041,555No comparison4SEC filing
May 5, 2009Initial$250,000No comparisonNot reportedSEC filing
May 5, 2009Initial$500No comparisonNot reportedSEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-308697

Source: Form D, filed Mar 27, 2018. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Paul Berns Director
Kristina Burow Director
Graham Cooper Director
Jamie Dananberg Executive
Nathaniel E. David Director, Executive
Troy Foster Executive
Bob Goeltz Executive
Keith Klein Executive
Keith Leonard Director, Executive
Dan Marquess Executive
Robert Nelsen Director
Camille Samuels Director
John Smither Executive
Tamara Tompkins Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
3280 Bayshore Boulevard
Brisbane, CA, 94005